Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral deferiprone in transfusion-dependent lower-risk myelodysplastic syndrome with iron overload
MOH_2017-11-02_001896Phase 2Recruiting
- Sponsor
- ד"ר מרקל דרורית
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferiprone in myelodysplastic syndrome (MDS), sponsored by ד"ר מרקל דרורית. Primary endpoint: Oxidative stress markers. Started Feb 2015; status: recruiting.
02
Drugs
deferiprone
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2017-11-02_001896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-02_001896.